



Neogap Therapeutics selected for the Innovate Nordics 2025 Acceleration Program

Neogap Therapeutics, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, is pleased to announce that it has been selected for the prestigious Innovate Nordics 2025 Acceleration Program, organised by the Swedish-American Chamber of Commerce in New York (SACCCNY) in partnership with EY.



Innovate Nordics targets Nordic growth companies aiming to establish a presence in the U.S. market. Following a highly competitive selection process, Neogap was selected as one of the companies gaining access to market insights, business development support, and investor networks in the United States. The programme includes virtual workshops, a kick-off event in Stockholm, and a final Grand Pitch Finale in New York in May.

"We are honoured to have been selected for Innovate Nordics 2025. The programme offers us a valuable opportunity to strengthen existing relationships, build new ones, and increase our access to the U.S. market. Each step we take brings us closer to our goal – making personalised cancer immunotherapy available to more patients," says Andrea Salmén, COO at Neogap Therapeutics.

This spring, Neogap will take part in the programme's kick-off event on 8 May in Stockholm, followed by a delegation visit to New York from 19 to 21 May, where the company will present its work at the Grand Pitch Finale before investors and potential partners.

Neogap's personalised immunotherapy, pTTL

Neogap is developing pTTL, a personalised, cell-based immunotherapy designed to enhance

the patient's own T cells to fight cancer. The therapy combines advanced DNA sequencing with T-cell expansion in a precision treatment for solid tumours and is based on Neogap's proprietary technologies, PIOR® and EpiTCer®. The aim is to offer patients a tailored and innovative therapy that meets their specific needs.

Neogap recently announced positive initial safety observations from the first two patients treated in its ongoing Phase I/II trial for advanced colorectal cancer. The initial safety data indicate that the treatment is well tolerated, with no serious treatment-related adverse events observed.



Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:

Samuel Svensson, CEO

Email: samuel.svensson@neogap.se

Phone: +46 733 54 21 94

About Neogap Therapeutics

Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit neogap.se and follow Neogap on [LinkedIn](#).